Výsledky vyhledávání

Akademický článek

Terms and Definitions Used to Describe Recurrence, Treatment Failure and Recovery of Acute Exacerbations of COPD: A Systematic Review of Observational Studies

Autor: Meeraus WH, DeBarmore BM, Mullerova H, Fahy WA, Benson VS

Publikováno v: International Journal of COPD, Vol Volume 16, Pp 3487-3502 (2021)

Wilhelmine H Meeraus,1 Bailey M DeBarmore,2 Hana Mullerova,1 William A Fahy,3 Victoria S Benson1 1Epidemiology – Value Evidence and Outcomes, Global Medical R&D, GlaxoSmithKline, Brentford, UK; 2Epidemiology – Value Evidence and Outcomes, Global

Externí odkaz: https://doaj.org/article/c7470de9353249c48bf7f2fa542695eb

Zobrazit plný text záznamu

Akademický článek

Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study

Autor: Fahy WA, Homayoun-Valiani F, Cahn A, Robertson J, Templeton A, Meeraus WH, Wilson R, Lowings M, Marotti M, West SL, Tabberer M, Hessel EM

Publikováno v: International Journal of COPD, Vol Volume 16, Pp 1637-1646 (2021)

William A Fahy,1 Farshid Homayoun-Valiani,2 Anthony Cahn,3 Jon Robertson,4 Alison Templeton,4 Wilhelmine H Meeraus,5 Robert Wilson,3 Mike Lowings,6 Miriam Marotti,7 Sarah L West,2 Maggie Tabberer,8 Edith M Hessel9 1Discovery Medicine, GlaxoSmithKline

Externí odkaz: https://doaj.org/article/781de99ff2da4683bff64e6e82bc03e4

Zobrazit plný text záznamu

Akademický článek

Predicting Re-Exacerbation Timing and Understanding Prolonged Exacerbations: An Analysis of Patients with COPD in the ECLIPSE Cohort

Autor: Meeraus WH, Mullerova H, El Baou C, Fahey M, Hessel EM, Fahy WA

Publikováno v: International Journal of COPD, Vol Volume 16, Pp 225-244 (2021)

Wilhelmine H Meeraus,1 Hana Mullerova,1 Céline El Baou,2 Marion Fahey,1 Edith M Hessel,2 William A Fahy2 1GlaxoSmithKline plc., Epidemiology – Value, Evidence and Outcomes, Middlesex, UK; 2GlaxoSmithKline plc., Research and Development, Middlesex,

Externí odkaz: https://doaj.org/article/16740186b7064aa2865013676e2c91cc

Zobrazit plný text záznamu

Forced vital capacity trajectories in patients with idiopathic pulmonary fibrosis: a secondary analysis of a multicentre, prospective, observational cohort

Publikováno v: e872
e862

Background Idiopathic pulmonary fibrosis is a progressive fibrotic lung disease with a variable clinical trajectory. Decline in forced vital capacity (FVC) is the main indicator of progression; however, missingness prevents long-term analysis of patt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62c323f869c37734f613aed9b1f1798d
https://doi.org/10.1016/s2589-7500(22)00173-x

Zobrazit plný text záznamu

Akademický článek

Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD

Autor: Singh S, Maltais F, Tombs L, Fahy WA, Vahdati-Bolouri M, Locantore N, Riley JH

Publikováno v: International Journal of COPD, Vol Volume 13, Pp 203-215 (2018)

Sally Singh,1 François Maltais,2 Lee Tombs,3 William A Fahy,4 Mitra Vahdati-Bolouri,4 Nicholas Locantore,5 John H Riley4 1Centre for Exercise and Rehabilitation Science, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester, UK;

Externí odkaz: https://doaj.org/article/92b3ad9a7133435f83024a036ece7a25

Zobrazit plný text záznamu

Akademický článek

Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study

Autor: Kerwin EM, Kalberg CJ, Galkin DV, Zhu C, Church A, Riley JH, Fahy WA

Publikováno v: International Journal of COPD, Vol Volume 12, Pp 745-755 (2017)

Edward M Kerwin,1 Chris J Kalberg,2 Dmitry V Galkin,2 Chang-Qing Zhu,3 Alison Church,2 John H Riley,4 William A Fahy4 1Clinical Research Institute of Southern Oregon, Medford, OR, 2Respiratory Department, GlaxoSmithKline, Research Triangle Park, NC,

Externí odkaz: https://doaj.org/article/cd5c25bdee7948b2aec8fa1bcd62e89f

Zobrazit plný text záznamu

Akademický článek

Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol

Autor: Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I

Publikováno v: International Journal of COPD, Vol 2016, Iss Issue 1, Pp 1413-1424 (2016)

Dave Singh,1 M Reza Maleki-Yazdi,2 Lee Tombs,3 Ahmar Iqbal,4 William A Fahy,5 Ian Naya5 1Medicines Evaluation Unit, University of Manchester, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK; 2Division of Respiratory Medic

Externí odkaz: https://doaj.org/article/2c14e91ea6c94f3db68289c865419cdf

Zobrazit plný text záznamu

Akademický článek

A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 µg on health-related quality of life in patients with COPD

Autor: Siler TM, Donald AC, O’Dell D, Church A, Fahy WA

Publikováno v: International Journal of COPD, Vol 2016, Iss Issue 1, Pp 971-979 (2016)

Thomas M Siler,1 Alison C Donald,2 Dianne O’Dell,2,3 Alison Church,2 William A Fahy4 1Midwest Chest Consultants, PC, St Charles, MO, 2GSK, Research Triangle Park, NC, USA; 3Pearl Therapeutics, Inc., Durham, NC, USA; 4GSK, Respiratory Medicines Deve

Externí odkaz: https://doaj.org/article/e6dd7313327f4e55b5ec2c0c4158d147

Zobrazit plný text záznamu

Akademický článek

A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 µg compared with tiotropium 18 µg in patients with COPD

Autor: Feldman G, Maltais F, Khindri S, Vahdati-Bolouri M, Church A, Fahy WA, Trivedi R

Publikováno v: International Journal of COPD, Vol 2016, Iss Issue 1, Pp 719-730 (2016)

Gregory Feldman,1 François Maltais,2 Sanjeev Khindri,3 Mitra Vahdati-Bolouri,3 Alison Church,4 William A Fahy,3 Roopa Trivedi4,5 1S. Carolina Pharmaceutical Research, Spartanburg, SC, USA; 2Institut universitaire de cardiologie et de pneumologie de

Externí odkaz: https://doaj.org/article/3fb848a2b028469581a9247d871c5fa5

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání